Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial: data from the GATEWAY trial (2019)
- Authors:
- Autor USP: DRAGER, LUCIANO FERREIRA - FM
- Unidade: FM
- DOI: 10.1016/j.soard.2018.11.022
- Subjects: HIPERTENSÃO; FATORES DE RISCO; DERIVAÇÃO GÁSTRICA; DOENÇAS METABÓLICAS; CARDIOPATIAS; ENSAIO CLÍNICO; ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Surgery for obesity and related diseases
- ISSN: 1550-7289
- Volume/Número/Paginação/Ano: v. 15, n. 2, p. 211-217, 2019
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SCHIAVON, Carlos Aurelio et al. Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial: data from the GATEWAY trial. Surgery for obesity and related diseases, v. 15, n. 2, p. 211-217, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.soard.2018.11.022. Acesso em: 23 jan. 2026. -
APA
Schiavon, C. A., Santos, R. N., Santucci, E. V., Noujaim, P. M., Cavalcanti, A. B., & Drager, L. F. (2019). Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial: data from the GATEWAY trial. Surgery for obesity and related diseases, 15( 2), 211-217. doi:10.1016/j.soard.2018.11.022 -
NLM
Schiavon CA, Santos RN, Santucci EV, Noujaim PM, Cavalcanti AB, Drager LF. Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial: data from the GATEWAY trial [Internet]. Surgery for obesity and related diseases. 2019 ; 15( 2): 211-217.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1016/j.soard.2018.11.022 -
Vancouver
Schiavon CA, Santos RN, Santucci EV, Noujaim PM, Cavalcanti AB, Drager LF. Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial: data from the GATEWAY trial [Internet]. Surgery for obesity and related diseases. 2019 ; 15( 2): 211-217.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1016/j.soard.2018.11.022 - Resistant hypertension: time to consider the best fifth anti-hypertensive treatment
- Rationale and methodology of the SARAH Trial: Long-term cardiovascular outcomes in patients with resistant hypertension and obstructive sleep apnea
- Bariatric Surgery for Resistant Hypertension: Working in Progress!
- OSA and cardiometabolic risk: What's the bottom line?
- Are we missing obstructive sleep apnea diagnosis?[Editorial]
- Apneia Obstrutiva do Sono e Aterosclerose: uma abordagem translacional
- Insomnia episodes, new-onset pharmacological treatments, and other sleep disturbances during the COVID-19 pandemic: a nationwide cross-sectional study in Brazilian health care professionals
- OSA and Prognosis After Acute Cardiogenic Pulmonary Edema The OSA-CARE Study
- Obstructive Sleep Apnea and Diabetes Independently Add to Cardiovascular Risk After Coronary Revascularization [Carta]
- Is obstructive sleep apnoea an innocent bystander in the pathophysiology of arterial stiffening? [Editorial]
Informações sobre o DOI: 10.1016/j.soard.2018.11.022 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
